

UNITED STATES BANKRUPTCY COURT

DISTRICT OF Delaware

In re: Zosano Pharma Corporation

Case No. 22-10506

Debtor(s)

§  
§  
§  
§

Jointly Administered

Post-confirmation Report

Chapter 11

Quarter Ending Date: 03/31/2023

Petition Date: 06/01/2022

Plan Confirmed Date: 11/22/2022

Plan Effective Date: 12/07/2022

This Post-confirmation Report relates to:  Reorganized Debtor

Other Authorized Party or Entity: Zosano Pharma Corporation Liquidating T  
Name of Authorized Party or Entity

/s/ Dennis A. Meloro  
Signature of Responsible Party

08/28/2023  
Date

Dennis A. Meloro  
Printed Name of Responsible Party

Greenberg Traurig LLP  
222 Delaware Avenue, Suite 1600  
Wilmington, DE 19801  
Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.



221050623082800000000002

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

**Part 1: Summary of Post-confirmation Transfers**

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	\$75,092	\$222,950
b. Non-cash securities transferred	\$0	\$0
c. Other non-cash property transferred	\$0	\$0
d. Total transferred (a+b+c)	\$75,092	\$222,950

**Part 2: Preconfirmation Professional Fees and Expenses**

a.			Approved Current Quarter	Approved Cumulative	Paid Current Quarter	Paid Cumulative
	Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor <i>Aggregate Total</i>		\$165,607	\$1,542,640	\$0	\$1,368,133
<i>Itemized Breakdown by Firm</i>						
	Firm Name	Role				
i	Greenberg Traurig, LLP	Lead Counsel	\$111,483	\$674,496	\$0	\$563,013
ii	SierraConstellation Partners LL	Financial Professional	\$13,206	\$190,903	\$0	\$177,697
iii	KURTZMAN CARSON CONS	Other	\$40,918	\$677,241	\$0	\$627,423
iv						
v						
vi						
vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

xxx						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xlix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

lxxii					
lxxiii					
lxxiv					
lxxv					
lxxvi					
lxxvii					
lxxviii					
lxxix					
lxxx					
lxxxi					
lxxxii					
lxxxiii					
lxxxiv					
lxxxv					
lxxxvi					
lxxxvi					
lxxxvi					
lxxxix					
xc					
xc					
xcii					
xciii					
xciv					
xcv					
xcvi					
xcvii					
xcviii					
xcix					
c					
ci					

			Approved Current Quarter	Approved Cumulative	Paid Current Quarter	Paid Cumulative	
b.	Professional fees & expenses (nonbankruptcy) incurred by or on behalf of the debtor		\$0	\$0	\$0	\$2,617	
	<i>Aggregate Total</i>						
	<i>Itemized Breakdown by Firm</i>						
		Firm Name	Role				
	i	BPM LLP	Financial Professional	\$0	\$0	\$0	\$2,617
	ii						
	iii						
	iv						
v							
vi							

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						
xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

xlix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

xcvii						
xcviii						
xcix						
c						
ci						
c.	All professional fees and expenses (debtor & committees)		\$165,607	\$1,542,640	\$0	\$1,370,750

**Part 3: Recoveries of the Holders of Claims and Interests under Confirmed Plan**

	Total Anticipated Payments Under Plan	Paid Current Quarter	Paid Cumulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	\$243,050	\$0	\$0	\$243,049	0%
b. Secured claims	\$0	\$0	\$0	\$0	0%
c. Priority claims	\$330,666	\$0	\$0	\$0	0%
d. General unsecured claims	\$1,222,701	\$0	\$0	\$10,600	0%
e. Equity interests	\$0	\$0	\$0		

**Part 4: Questionnaire**

- a. Is this a final report? Yes  No
- If yes, give date Final Decree was entered: \_\_\_\_\_
- If no, give date when the application for Final Decree is anticipated: \_\_\_\_\_
- b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes  No

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506

**Privacy Act Statement**

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: [http://www.justice.gov/ust/eo/rules\\_regulations/index.htm](http://www.justice.gov/ust/eo/rules_regulations/index.htm). Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

**I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.**

/s/ Bill Partridge

\_\_\_\_\_  
Signature of Responsible Party

Managing Director

\_\_\_\_\_  
Title

Bill Partridge

\_\_\_\_\_  
Printed Name of Responsible Party


08/28/2023

\_\_\_\_\_  
Date




Debtor's Name Zosano Pharma Corporation


Case No. 22-10506




Page 1



Other Page 1



Page 2 Minus Tables




Bankruptcy Table 1-50

Debtor's Name Zosano Pharma Corporation

Case No. 22-10506




Bankruptcy Table 51-100



Non-Bankruptcy Table 1-50



Non-Bankruptcy Table 51-100



Part 3, Part 4, Last Page